Evolus
EOLS
113 hedge funds and large institutions have $135M invested in Evolus in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
77% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $2.55M
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
2.32% more ownership
Funds ownership: 29.98% → 32.3% (+2.3%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 115 → 113 (-2)
34% less capital invested
Capital invested by funds: $205M → $135M (-$70.4M)
Top Buyers
| 1 |
First Manhattan
New York
|
+$6.69M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$4.09M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.33M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$3.1M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.1M |
Top Sellers
| 1 |
TLP
Tri Locum Partners
New York
|
-$6.29M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$4.99M |
| 3 |
SG Americas Securities
New York
|
-$4.45M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$3.4M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$2.53M |
EOLS Hedge Fund Activity: Q3 2021 in Review
113 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Evolus (EOLS) for Q3 2021, worth a combined $135M — down 34% from $205M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of EOLS and 15 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 43 added.
The largest buyer was First Manhattan, adding an estimated $6.69M. The largest seller was Tri Locum Partners, exiting entirely with an estimated $6.29M sold.
- 113 institutional investors held Evolus (EOLS) as of Q3 2021, down from 115 in Q2 2021.
- Funds reported $135M of Evolus stock for Q3 2021, down 34% quarter-over-quarter.
- 15 funds opened new Evolus positions in Q3 2021 and 16 closed out, a net change of -1 holder.
- The largest Evolus buyer in Q3 2021 was First Manhattan, an estimated $6.69M added.
- The largest Evolus seller in Q3 2021 was Tri Locum Partners, an estimated $6.29M sold.
Based on aggregated 13F filings for Q3 2021.